Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
The Leonid meteor shower is peaking early this week. Here’s what to know - 2The Most Compelling Innovation Developments Somewhat recently
- 3This Canadian crater looks like marbled meat | Space photo of the day for Jan. 6, 2026
- 4Analysis-From 'Icarus bug' to flawed panels: Airbus counts cost of relying on single model
- 5Guns N' Roses 2026 Tour: How to get tickets, presale times, prices and more
- From Novice to Master: Dominating a Side interest
- Brazil's ex-president Bolsonaro operated on for hernia
- Instructions to Help a Friend or family member Determined to have Cellular breakdown in the lungs
- Our favorite Space.com stories of 2025
- The Specialty of Compromise: Examples from Reality
- Aurora chaser catches a fox basking in the glow of Finland's legendary 'fox fires' (photos)
- Hungary's 'water guardian' farmers fight back against desertification
- Birds at a college changed beak shapes during the pandemic. It might be a case of rapid evolution
- Vote in favor of the bloom plan that adds a bit of excellence to your life!
